Project Number 5R01AG062463-04 Agency/Funding Organization NIA Funding Year 2022 View Full Project Details for A randomized, double blind, placebo-controlled study to evaluate the impact of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB) Research Categorization Primary Disease / Condition Lewy Body Dementias CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) m. Synaptic Plasticity/Neuroprotection Researcher and Organization Principal Investigator MOUSSA, CHARBEL Principal Investigator First Name CHARBEL Principal Investigator Last Name MOUSSA Awardee Organization GEORGETOWN UNIVERSITY Awardee State District of Columbia Contact PI Country United States Project Detail Funding Opportunity Announcement PAR-18-175: Pilot Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional) FY Overall Cost $1,417,321 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official CLARKE, AKANNI YAO
